Inhibikase Therapeutics Inc (IKT)

Feb 18, 2025

Inhibikase Therapeutics Appoints Mark Iwicki as New CEO - TipRanks

Feb 18, 2025

Feb 18, 2025

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire

Feb 18, 2025

Feb 18, 2025

Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan

Feb 18, 2025

Feb 17, 2025

What is HC Wainwright’s Estimate for IKT Q1 Earnings? - Defense World

Feb 17, 2025

Feb 15, 2025

HC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT) - MSN

Feb 15, 2025

Feb 15, 2025

Inhibikase Therapeutics (NYSE:IKT) Lowered to Neutral Rating by HC Wainwright - MarketBeat

Feb 15, 2025

Feb 15, 2025

Inhibikase Therapeutics (NYSE:IKT) Cut to Neutral at HC Wainwright - Defense World

Feb 15, 2025

Feb 12, 2025

HC Wainwright & Co. Downgrades Inhibikase Therapeutics (MUN:IQT0) - Nasdaq

Feb 12, 2025

Feb 12, 2025

This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga

Feb 12, 2025

Feb 12, 2025

HC Wainwright Downgrades Inhibikase Therapeutics to Neutral From Buy -February 12, 2025 at 07:59 am EST - Marketscreener.com

Feb 12, 2025

Feb 01, 2025

Inhibikase Therapeutics (NYSE:IKT) Stock Price Down 2.5%What's Next? - MarketBeat

Feb 01, 2025

Jan 31, 2025

Inhibikase Thera falls as risvodetinib development paused - The Pharma Letter

Jan 31, 2025

Jan 31, 2025

Insiders Enjoy US$1.1m Return After Buying Inhibikase Therapeutics Stock - Simply Wall St

Jan 31, 2025

Jan 30, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 30, 2025

Jan 30, 2025

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study - MSN

Jan 30, 2025

Jan 30, 2025

Inhibikase Halts Parkinson's Drug Development to Focus on PAH - MSN

Jan 30, 2025

Jan 30, 2025

Stock market today: Aclarion -99.69%, CARGO Therapeutics -76.31% among biggest losers in early trading - Business Upturn

Jan 30, 2025

Jan 28, 2025

Inhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% – Should You Sell? - Defense World

Jan 28, 2025

Jan 21, 2025

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing R - GuruFocus.com

Jan 21, 2025

Jan 21, 2025

Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock - Yahoo Finance

Jan 21, 2025

Jan 15, 2025

Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR

Jan 15, 2025

Jan 13, 2025

Top 5 Small-cap Pharma Stocks (Updated January 2025) - Investing News Network

Jan 13, 2025

Jan 07, 2025

Inhibikase Therapeutics Completes Amendment to Certificate of IncorporationAtlanta, Georgia – Inhibikase Therapeutics, Inc. (NYSE:IKT) recently announced the successful completion of a Special Meeting of Stockholders on January 3, 2025. During this m - Defense World

Jan 07, 2025

Jan 06, 2025

Inhibikase Therapeutics expands authorized shares - Investing.com India

Jan 06, 2025

Jan 06, 2025

Inhibikase Therapeutics expands authorized shares By Investing.com - Investing.com Australia

Jan 06, 2025

Dec 28, 2024

Contrasting CRISPR Therapeutics (NASDAQ:CRSP) & Inhibikase Therapeutics (NYSE:IKT) - Defense World

Dec 28, 2024

Dec 27, 2024

Inhibikase Therapeutics (NYSE:IKT) Trading 3.4% HigherTime to Buy? - MarketBeat

Dec 27, 2024

Dec 27, 2024

Inhibikase Therapeutics (NYSE:IKT) Trading 3.4% Higher – Still a Buy? - Defense World

Dec 27, 2024

Dec 20, 2024

Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com

Dec 20, 2024

Dec 20, 2024

Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com

Dec 20, 2024

Dec 16, 2024

Inhibikase Therapeutics Hits 52-Week High, Surpassing Market Expectations with 198% Growth - mediahousepress

Dec 16, 2024

Dec 16, 2024

Inhibikase stock soars to 52-week high, hits $3.88 - Investing.com

Dec 16, 2024

Dec 16, 2024

Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews

Dec 16, 2024

Dec 07, 2024

Inhibikase Therapeutics Terminates At the Market Offering Agreement - Defense World

Dec 07, 2024

Dec 05, 2024

Inhibikase Therapeutics ends agreement with sales agent By Investing.com - Investing.com Canada

Dec 05, 2024

Dec 05, 2024

Inhibikase Therapeutics ends agreement with sales agent - Investing.com

Dec 05, 2024

Nov 30, 2024

Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 7% – What’s Next? - Defense World

Nov 30, 2024

Nov 30, 2024

Inhibikase Therapeutics (NYSE:IKT) Shares Up 7%Here's Why - MarketBeat

Nov 30, 2024

Nov 19, 2024

Inhibikase: Potential To Improve Current Treatment Options For PAH Patients - Seeking Alpha

Nov 19, 2024

Nov 18, 2024

Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders - TipRanks

Nov 18, 2024

Nov 15, 2024

ARMISTICE CAPITAL, LLC Expands Stake in Inhibikase Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Inhibikase Therapeutics Inc (IKT) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 14, 2024

Inhibikase Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 14, 2024

Nov 14, 2024

Inhibikase Therapeutics reports Q3 EPS (65c), consensus (48c) - TipRanks

Nov 14, 2024

Nov 14, 2024

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity - The Bakersfield Californian

Nov 14, 2024

Nov 14, 2024

Inhibikase Secures $275M Financing Deal, Advances PAH Drug Trial Despite Q3 Loss | IKT Stock News - StockTitan

Nov 14, 2024

Nov 08, 2024

Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential - Investing.com

Nov 08, 2024